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Methicillin-resistant Staphylococcus aureus (MRSA) is 
a major cause of healthcare- and community-associ-
ated infections worldwide. Within the healthcare set-
ting alone, MRSA infections are estimated to affect 
more than 150,000 patients annually in the European 
Union (EU), resulting in attributable extra in-hospital 
costs of EUR 380 million for EU healthcare systems. 
Pan-European surveillance data on bloodstream infec-
tions show marked variability among EU Member 
States in the proportion of S. aureus that are methi-
cillin-resistant, ranging from less than 1% to more 
than 50%. In the past five years, the MRSA bacterae-
mia rates have decreased significantly in 10 EU coun-
tries with higher endemic rates of MRSA infections. 
In addition to healthcare-associated infections, new 
MRSA strains have recently emerged as community- 
and livestock-associated human pathogens in most EU 
Member States. The prevention and control of MRSA 
have therefore been identified as public health priori-
ties in the EU. In this review, we describe the current 
burden of MRSA infections in healthcare and com-
munity settings across Europe and outline the main 
threats caused by recent changes in the epidemiology 
of MRSA. Thereby, we aim at identifying unmet needs 
of surveillance, prevention and control of MRSA in 
Europe.
Introduction
Concern about the burden of healthcare-associated 
infections (HAIs) has a significant European dimension. 
It has been estimated that 8–12% of patients admit-
ted to hospitals in European countries suffer from 
adverse events while receiving healthcare, with HAIs 
being the most prominent of them [1]. The European 
Centre for Disease Prevention and Control (ECDC) has 
calculated that HAIs involve 4.1 million patients annu-
ally in the European Union (EU) Member States and that 
such infections directly result in approximately 37,000 
deaths [1]. This worrisome incidence of HAIs is rightly 
considered a major patient safety issue. Another 
cause for concern is the continuous emergence of vari-
ous multidrug-resistant bacteria in many healthcare 
institutions, which narrows the spectrum of effective 
antibiotics to a clinically challenging extent. Against 
this background, the Council of the EU has recently 
launched a recommendation to Member States and 
the Commission to prevent HAIs and promote patient 
safety by community, national and institutional action 
plans [1].
Among the multiresistant bacteria, methicillin-resist-
ant Staphylococcus aureus (MRSA) is a major cause 
of HAIs in the EU. In 2008, over 380,000 HAIs due to 
selected antibiotic-resistant bacteria, including those 
of the bloodstream, lower respiratory tract, skin or 
soft tissues and urinary tract, were estimated to be 
acquired annually in hospitals of the EU Member 
States, Iceland and Norway [2]. Overall, MRSA accounts 
for 44% (n=171,200) of these HAIs, 22% (n=5,400) of 
attributable extra deaths and 41% (n=1,050,000) of 
extra days of hospitalisation associated with these 
infections [2]. The attributable extra in-hospital costs 
caused by MRSA are estimated to reach approximately 
EUR 380 million annually [2]. Moreover, the vast extent 
of MRSA infections has both evoked fear and fuelled 
public distrust about healthcare. For many healthcare 
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consumers, this has made MRSA bloodstream infection 
rates an indicator of both quality of care and outcome.
In addition to the healthcare settings (healthcare-asso-
ciated methicillin-resistant Staphylococcus aureus, 
HA-MRSA) [3], the burden of MRSA colonisation and 
infection has recently expanded to further ecological 
niches. Since the 1990s, an increasing incidence of 
MRSA infections arising in the community (community-
associated methicillin-resistant Staphylococcus aureus, 
CA-MRSA) has been reported from many countries 
worldwide [3]. More recently, MRSA have been found 
to colonise or infect livestock and humans exposed to 
those animals in several countries. Such MRSA have 
been dubbed livestock-associated methicillin-resist-
ant Staphylococcus aureus (LA-MRSA) [4]. Interactions 
between these different reservoirs for MRSA have been 
reported, including nosocomial infections by CA-MRSA 
[5,6] and importation of LA-MRSA into hospitals [7].
MRSA is amongst the most challenging infection con-
trol issues. In this review, we delineate the burden 
of MRSA disease in Europe across healthcare sectors 
and review the economic impact of MRSA infections. 
Finally, we outline threats due to recent changes in 
the epidemiology of MRSA and identify unmet needs 
regarding surveillance, prevention and control of MRSA 
in Europe.
Methods
We searched PubMed and supplemented this with arti-
cles from our personal archives to retrieve the literature 
for this review. For the PubMed search, a restriction to 
articles published between 2001 and 2009 and writ-
ten in English was applied. Our review is structured in 
two sections: (i). Epidemiology and burden of MRSA 
infections, in which we outline the main determinants 
of MRSA disease burden, compared to infections by 
methicillin-susceptible S. aureus (MSSA), and sum-
marise recent trends in the epidemiology of MRSA in 
Europe in healthcare facilities, the community and 
livestock; and (ii). Discussion on new reservoirs and 
control challenges, where, against the background of 
data described in the first section, we identify poten-
tial threats from the current epidemiology of MRSA in 
Europe and discuss perspectives for the prevention 
and control of MRSA in European countries.
Epidemiology and burden 
of MRSA infections
Burden of disease
Monitoring the epidemiology and the burden of MRSA 
infections in European countries is crucial. This has 
been underlined by the finding that MRSA does not just 
replace MSSA as a causative agent for infections, but 
frequently adds to the latter’s disease burden, leading 
to a net increase in the incidence of S. aureus infec-
tions (Table 1) [8,9]. 
Moreover, it has been debated whether MRSA bacter-
aemia causes higher mortality than MSSA bacteraemia, 
e.g. due to vancomycin’s inferiority in the treatment of 
deep-seated S. aureus infections, compared with semi-
synthetic penicillins, compared with semi-synthetic 
penicillins used for MSSA [10]. Two meta-analyses 
have found an increased mortality risk of 1.93 (95% CI: 
1.54 to 2.42) [10] and 2.03 (95% CI: 1.55 to 2.65) [11] 
associated with MRSA bacteraemia compared with 
MSSA. However, there is an ongoing discussion about 
methodological flaws of the studies included in these 
meta-analyses, e.g. with respect to whether they fully 
adjusted for appropriateness of therapy and severity 
of underlying diseases. Table 2 contains an update of 
additional (published between 2001 and 2009) regard-
ing this issue: their results still do not clearly answer 
the initial question. 
Besides effects on mortality, several studies mainly 
from the USA have indicated that MRSA infections 
cause a significant additional financial burden over 
Table 1
Key elements in the recent epidemiology of MRSA infections in Europe
Characteristic Summary
MRSA vs MSSA infections
Recent investigations indicate that:
•	 MRSA	adds	to	the	total	burden	of	S. aureus disease; 
•	 Invasive	MRSA	infections	are	associated	with	a	higher	mortality	compared	with	MSSA;
•	 MRSA	infections	generate	extra	costs	of	care	mainly	due	to	prolonged	length	of	hospital	stay.
Epidemiological reservoirs In European countries, MRSA is associated with three main reservoirs: healthcare institutions (HA-MRSA), the community (CA-MRSA), and livestock (LA-MRSA).
HA-MRSA According to the pan-European surveillance systems, EARSS and HELICS, the prevalence of HA-MRSA infection markedly varies between countries but has been decreasing in several over the past five years.
CA-MRSA CA-MRSA infections have emerged in most European countries but are still less frequent overall than HA-MRSA infections.
LA-MRSA In the majority of European countries, livestock is colonised with MRSA. The impact of this reservoir on public health is unclear.
CA-MRSA: community-associated methicillin-resistant Staphylococcus aureus; EARSS: European Antimicrobial Resistance Surveillance 
System; HA-MRSA: healthcare-associated methicillin-resistant Staphylococcus aureus; HELICS: Hospital in Europe Link for Infection Control 
through Surveillance; LA-MRSA: livestock-associated methicillin-resistant Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus 
aureus; MSSA: methicillin-susceptible Staphylococcus aureus.
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MSSA infections after adjustment for co-morbidities, 
which is largely the result of prolonged hospital stay 
and occupation of isolation rooms (Table 3). 
Moreover, a Dutch study has recently estimated that 
the implementation of a MRSA ’search and destroy’ 
policy was highly cost–effective in one hospital under 
investigation [29]. During the study period, no MRSA 
bacteraemia was observed in this hospital. Assuming 
that 50% of all nosocomial S. aureus would be MRSA, if 
no search and destroy strategy had been implemented 
the authors estimated 36 MRSA bacteraemia cases per 
year were thus avoided [29].
Furthermore, it has been found that MRSA carriers are 
at risk for MRSA infection, since up to 29% of persons 
colonised with MRSA subsequently develop MRSA mor-
bidity [30,31]. For example, MRSA carriers in long-term 
care facilities have a 1.4-fold increased risk for mortal-
ity within 36 months [32] and 5% of long-term carriers 
have been shown to die because of an MRSA infection 
within four years of carriage [30].
Epidemiology of healthcare-associated MRSA
Nosocomial infections acquired by patients receiving 
institutional healthcare have long been the classical 
presentation of MRSA infections. Risk factors for MRSA 
acquisition include hospital care, care in chronic care 
facilities and nursing homes for elderly people, pres-
ence of indwelling devices or chronic wounds and pre-
vious antibiotic treatment.
The majority of HA-MRSA strains isolated in European 
countries have emerged from the introduction of the 
staphylococcal cassette chromosome mec (SCCmec) 
harbouring the methicillin-resistance gene mecA, into 
five S. aureus clonal complexes (CC), as defined by 
multi–locus sequence typing (MLST): CC5, CC8, CC22, 
CC30 and CC45 [3].
Recent data on the burden of HA-MRSA disease on 
a European scale are available from two surveil-
lance systems supported by ECDC (EARSS, HELICS). 
The European Antimicrobial Resistance Surveillance 
System (EARSS) is used in most European countries to 
record the incidence of bloodstream and cerebrospinal 
MRSA infections, representing severe clinical courses 
of (mostly HA-) MRSA morbidity. As shown recently, 
hospitals contributing to EARSS provide care for about 
20% of the EU population, accession countries and 
Israel [33]. However, EARSS coverage ranges between 
5% and 100%, depending on the country, and therefore 
representative data from all countries are not avail-
able [33]. In 2008, the proportion of MRSA in S. aureus 
blood culture isolates was less than 5% in Denmark, 
Estonia, Finland, Iceland, the Netherlands, Norway 
and Sweden. In three countries (Austria, Luxembourg, 
Slovenia), a proportion of less than 10% was found, 
while in eight countries the proportion was between 
10%-24% (Belgium, Czech Republic, France, Germany, 
Hungary, Latvia, Poland, Switzerland) In total, 13 coun-
tries reported a proportion equal to or above 25% 
(Bulgaria, Croatia, Cyprus, Greece, Israel, Italy, Malta, 
Portugal, Republic of Ireland, Romania, Spain, Turkey, 
United Kingdom) including two countries (Malta, 
Portugal) with proportions above 50% [33]. 
The attributable fraction of HAI caused by MRSA is 
documented by the EU-wide surveillance network of 
infections in intensive care units (ICUs), which was 
established under the name “HELICS”. In 2007, the 
HELICS network (involving 13 European countries) 
reported that, of 54,574 patients staying in an ICU 
for more than two days, 6.2% acquired pneumonia. 
Overall, 17% of all cases of ICU-acquired pneumonia 
[34] were caused by S. aureus, 33% of which were 
MRSA. Moreover, ICU-acquired BSIs were caused by 
S.  aureus in 11% of all 4,812 cases included in the 
report with an MRSA proportion of 42% [34]. 
According to EARSS 2008 data, a significant declining 
trend of invasive MRSA infections has been observed 
in Austria, Poland, Latvia, Romania, Italy, France, 
Belgium and the United Kingdom over the last four 
years of surveillance [33]. Likewise, there was a signifi-
cant decrease in the mean incidence of ICU-acquired 
MRSA infection reported via HELICS between 2004 and 
2007 [34]. These trends illustrate that many European 
countries have experienced successes in the preven-
tion and control of MRSA in the healthcare setting as 
indicated by either continuously low incidence rates or 
recently decreasing rates of MRSA infections.
Epidemiology of community-associated MRSA
Until the 1990s, infections due to MRSA were rarely 
observed in the community. Since then, a rapid emer-
gence of CA-MRSA was first reported from Australia 
and the USA, where outbreaks were described amongst 
underprivileged aboriginal communities, schoolchil-
dren, prison inmates, soldiers, athletes and men who 
have sex with men [35]. These communities have not 
been reported so far as major reservoirs for CA-MRSA 
in Europe. Risk factors for the development of CA-MRSA 
infection include close contact with other people with 
CA-MRSA, e.g. having a family member from a country 
with a high prevalence of CA-MRSA, living in crowded 
facilities, poor hygiene, sharing of personal items 
and performing contact sports [36,37]. These obser-
vations help to elucidate the spread of MRSA outside 
healthcare settings. So far, the most important risk 
factor for CA-MRSA infections in many European coun-
tries is travel to countries with a higher prevalence of 
CA-MRSA [38-40].
CA-MRSA causes mainly skin- and soft-tissue infec-
tions ranging in severity from furuncles to necrotising 
fasciitis [37]. Moreover, the description of serious inva-
sive CA-MRSA infections, such as necrotising pneumo-
nia, is cause for concern, because these infections are 
associated with a lethality of up to 75% [41]. 
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The epidemic rise in CA-MRSA infections in the USA 
was mainly due to the successful spread of an MRSA 
strain associated with the pulsed-field gel electro-
phoresis (PFGE) profile USA300 within the MLST ST8/
SCCmec IV clone and harbouring the lukS-lukF genes, 
encoding the Panton-Valentine leukocidin (PVL) [35]. 
Other clones have contributed to this epidemic to a 
lesser extent [3].
In several European countries, infections due to the 
predominant USA clone (USA300/ST8) have also been 
reported [39,42-44]. However, the spread of this 
clone seems hitherto limited in Europe where other 
PVL-positive CA-MRSA clones, especially ST80/t044/
SCCmec IV, are also prevalent [3,46].
Defining the overall burden of CA-MRSA in European 
countries and comparing proportions of CA-MRSA 
among all MRSA isolates between different studies is 
hindered by differences in the definitions used [37]. 
However, the proportion of CA-MRSA with respect to 
total MRSA is reported to range between 1% and 2% 
in Spain and Germany [42,43] and 29–56% in Denmark 
and Sweden, partly reflecting the low prevalence of 
HA-MRSA in these Scandinavian countries [47,48]. 
Among outpatients with S. aureus infections, MRSA 
accounted for 6% in the Ligurian region in Italy [49], 
14% in Germany [50], 18% in France [51] and 30% in 
Greece [52].
Epidemiology of livestock-associated MRSA
Recently, it has been found that the burden of MRSA 
colonisation and infection also involves animals, par-
ticularly livestock. In Europe, a recent survey published 
by the European Food Safety Authority (EFSA) identified 
MRSA in pig holdings of 17 EU Member States [53]. The 
MRSA clone, which was isolated from the vast majority 
of pigs, was non-typeable by PFGE after SmaI digestion 
– due to DNA methylation not, however, affecting the 
SmaI isoschizomer Cfr9I [54] – was tetracycline-resist-
ant, and belonged to MLST CC398 [53].Besides swine, 
MRSA CC398 strains have also been detected in other 
animals such as  cattle [55] and poultry [4]. Although 
the animals are mostly colonised by MRSA, infections 
have been described in pigs [56] and horses [57].
The impact of a livestock reservoir for humans is cur-
rently under investigation. Whereas 23–38% of per-
sons having contact with MRSA-positive pigs or veal 
calves were colonised with MRSA [7,58,59], only 4% of 
their family members, who had no direct exposure to 
the animals, were colonised in one study [60]. In areas 
with a high density of MRSA CC398-positive swine, 
this clone can influence the MRSA epidemiology mark-
edly in healthcare settings. For instance, it has led to a 
three-fold increase in MRSA incidence over a few years 
in a Dutch hospital located in a pig-dense area [7], and, 
in a German hospital situated in a region with intense 
livestock farming, 22% of MRSA patients colonised 
with MRSA at hospital admission carried it [61]. 
This continuous import of MRSA CC398 from an ani-
mal reservoir into hospitals can result in nosocomial 
spread of MRSA to patient groups susceptible to the 
development of MRSA infections [44]. Nosocomial 
transmission of MRSA CC398 has indeed been reported 
[62]. Moreover, this strain has caused severe human 
infections such as endocarditis, soft-tissue infections 
and ventilator-associated pneumonia [63-65].
Nevertheless, the burden of human infections caused 
by MRSA CC398 in Europe remains poorly understood. 
The proportion of MRSA CC398 among all MRSA ranges 
from 0.3% in Germany [65] to 41% in the Netherlands 
[66]. Matters of further concern include the facts that 
PVL-encoding genes have been detected in a few MRSA 
CC398 isolates [67] and a cfr plasmid conferring resist-
ance against oxazolidinones was found in an MRSA 
CC398 background [68]. 
Another potential human health threat is related to 
food contamination with MRSA, which was documented 
by a Dutch study in 11.9% of retail meat products from 
several animal species, including beef (10.6%), pork 
(10.7%) and chicken (16%) [69]; detection by use of
enrichment cultures only suggests low quantity con-
tamination. The majority of these isolates belonged 
to the CC398 lineage, with only 15% to other clonal 
lineages [69]. To date, two outbreaks of human dis-
ease have been related to the consumption of MRSA-
contaminated meat, one as a classical food intoxication 
[70] and the other with contaminated food as the source 
of nosocomial transmission [71]. Both were caused by 
non-CC398 MRSA strains. Thus, presently, food does 
not seem to be an important source for MRSA transmis-
sion or infection. 
New reservoirs and control challenges
The recently decreasing or maintained low-level inci-
dence of HA-MRSA in BSIs in many European countries 
[33] is encouraging. In a majority of countries, these 
successes can be linked to the implementation of multi–
faceted preventive interventions (including measures 
focussing on screening, contact precautions, decolo-
nisation, antibiotic stewardship, or bundles of preven-
tive measures and care). In France, a national hospital 
infection control programme has been initiated and 
developed over 16 years, resulting in a 30% reduction 
of surgical site infections and a 20% decrease in MRSA 
rates from blood cultures [72]. In Belgium, a sustained 
decrease in the incidence of HA-MRSA infections was 
recorded between 2004 and 2008, measureable as a 
decrease in the mean proportion of MRSA of S. aureus 
(30–25%) and a decrease in the median incidence of 
nosocomial MRSA (3.2 to 1.6 per 100 admissions) [73]. 
This success has been achieved by a multi–faceted 
approach, including the update and strengthening of 
national MRSA guidelines, the extension of prospective 
surveillance and screening activities [74], and activi-
ties to promote the prudent use of antibiotics [75]. In 
England, a governmental reduction target in MRSA 
bacteraemia was set in 2004, demanding halving the 
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number of MRSA isolated from blood cultures by 2008, 
against the baseline of 2003–2004. In order to achieve 
this aim, a bundle of measures was consecutively 
implemented in English hospitals, including the man-
datory reporting of all MRSA bacteraemia by the hos-
pital chief executive officers, public benchmarking of 
MRSA incidence rates, the production of guidance on 
preventing HAIs, the establishment of a national hand 
hygiene campaign, prudent use of antibiotics, and the 
implementation of so called ’high impact interven-
tions’, i.e. care bundles focussing on key clinical pro-
cedures that can increase the risk of infection if not 
performed appropriately (e.g. central venous catheter 
care) [76]. After five years, data confirm a 62% reduc-
tion in the incidence of MRSA from blood cultures in 
England [77].
To what extent the multi–faceted approaches linked 
to the decreasing trends in MRSA infections in these 
countries can serve as examples of good practice for 
planning and implementing national control interven-
tions in other EU countries with different healthcare 
structures and resource attribution, remains to be 
seen.
Nevertheless, the burden of HA-MRSA extends beyond 
acute care hospitals to long-term care facilities (LCTFs), 
such as nursing homes. This has been underlined in 
several studies showing high prevalence rates of MRSA 
carriage among LTCF residents and marked rate varia-
tion between nursing homes and regions in Belgium 
(2–43%) [78], Germany (1%) [79], Spain (16%) [80], 
France (38%) [81] and the UK (5–23%) [82,83]. Despite 
this variation, in the majority of cases, the clonal struc-
ture of MRSA isolates from nursing home residents was 
closely related to that found among patients in neigh-
bouring acute care hospitals [78]. In addition, a recent 
study has shown that within six weeks after discharge 
from a hospital, less than 14% of LTCF residents are 
readmitted [84], which highlights that an appreciable 
percentage of patients circulates between hospital and 
LTCF several times per year. Consequently, effective 
MRSA containment in the healthcare setting cannot be 
limited to acute care hospitals, but must include LCTFs 
also. Otherwise, the significant MRSA reservoir that 
has developed in LTCFs and the transmission dynam-
ics between LTCFs and acute care hospitals due to the 
transfer of patients is bound to compromise control. 
That this problem may be underestimated is indeed 
suggested by an admittedly limited number of pub-
lished investigations [85].
A second challenge concerns CA-MRSA which has now 
emerged across Europe. Although its prevalence is 
still considerably lower than in the USA, the number 
of CA-MRSA infections appears to be increasing, espe-
cially in those European countries where the incidence 
of HA-MRSA is low and surveillance of MRSA more 
extensive [30,31]. The problem of CA-MRSA infections 
is not limited to the community but also affects noso-
comial infections due to the introduction of CA-MRSA in 
healthcare settings [86,87]. In addition, only a limited 
number of European countries have developed national 
strategies and no common European strategy has yet 
been developed for the surveillance or the prevention 
of CA-MRSA spread.
The final challenge to tackle is the animal MRSA reser-
voir. Despite the EU-wide spread of MRSA in pigs, its 
implications for humans directly or indirectly exposed 
to livestock and for patients attending healthcare 
institutions located in farming areas remain unclear. 
Although epidemic spread of LA-MRSA among persons 
without direct contact to animals is rare, and the bur-
den of human infections caused by LA-MRSA strains is 
still lower than that observed for CA-MRSA, infection 
control guidelines in many European countries should 
address the potential risk of acquiring MRSA via con-
tact with livestock farming.
Conclusions
MRSA infections constitute an important and still 
evolving public health challenge for European coun-
tries. Successful MRSA control in some countries and 
facilities offers opportunities for identifying effective 
interventions and reassessment of best practice. In con-
trast, the rapid emergence of MRSA in the community 
and in livestock underpins the fact that MRSA trans-
mission can occur in everyday life, in home care, dur-
ing travel, leisure activities, cross-border commuting, 
Table 4
Controlling MRSA: public health challenges and perspectives
Objective Need for improvement
Strengthening prevention and control of HA-MRSA Systematic assessment of effectiveness of MRSA control strategies and review of national guidelines for MRSA prevention and control 
Control of emerging threats Guidance on the prevention and control of CA-MRSA, LA-MRSA and HA-MRSA in long-term care facilities
Intersectoral coordination Coordinated actions to control the spread of MRSA between different healthcare sectors (hospitals, long-term care facilities, ambulatory care) and veterinary care
European healthcare cooperation European-wide concerted actions to control cross-border MRSA spread
CA-MRSA: community-associated methicillin-resistant Staphylococcus aureus; HA-MRSA: healthcare-associated methicillin-resistant 
Staphylococcus aureus; LA-MRSA: livestock-associated methicillin-resistant Staphylococcus aureus; MRSA: methicillin-resistant 
Staphylococcus aureus.
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exposure to contaminated food samples or livestock 
transport. For long-term success in controlling MRSA, 
coordinated actions between different healthcare sec-
tors (acute, long-term, ambulatory) and veterinary 
care are warranted and concerted efforts at European 
level will be of increasing importance. These efforts 
should begin with an agreement upon definitions for 
CA- and LA-MRSA and continue with the improvement 
of evidence-based guidance and the implementation of 
preventive measures to result in better prevention and 
control of MRSA in Europe (Table 4).
* Erratum: by mistake, a wrong table (Table 2) was posted with the 
original article. We apologise for this error and corrected it on 15 
October 2010.
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